Atnahs acquires rights to established hypertension medicines

Basildon / Cambridge (UK), 27 January 2020 – Atnahs, a Triton Fund V portfolio company, has signed an agreement to acquire the global (ex-China, India, Japan and US) commercial rights to a portfolio of Cardiovascular medicines used primarily to treat hypertension – namely, Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) from AstraZeneca.

Founded in 2013, Atnahs has significantly increased its product portfolio since inception through its strong relationships with leading pharma companies. The acquisition is a further step for Atnahs to deliver medicines that patients, prescribers, healthcare systems and regulators value as well as building out its Cardiovascular product portfolio. It also underlines the company’s strong track record of being a preferred acquirer for large cap or specialty pharma businesses choosing to divest their established brands.  

“The acquisition is strategically important and strengthens our position in Cardiovascular medicines. We consider these established medicines as highly trusted by patients and prescribers alike, and as very stable globally. The acquisition of these high-quality brands increases our size and diversification significantly”, says Dr. Amit Patel, CEO of Atnahs.